Company Profile
MacroGenics Stock Price, News & Catalysts
- Ticker:
- MGNX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.13 USD (+1.23%)
Close
Last updated: September 17, 2026
257M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, MGNX closed up 1.23% at $4.13. No new same-company headline was identified in the current news window.
Company overview
Antibody Engineering Company
MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates.
ADC Portfolio
MGC026 targets B7-H3 and is in Phase 1 dose expansion, while MGC028 targets ADAM9 and is in Phase 1 dose escalation across advanced solid tumors.
Focused R&D Model
Following divestiture of its manufacturing operation, MacroGenics is concentrating resources on drug discovery, clinical development, partnerships, and royalty interests such as ZYNYZ.
Future catalysts
- Initiation of the Phase 1 dose-escalation study of MGC030 in the third quarter of 2026.
- MGC026 and lorigerlimab clinical data presentations at ESMO 2026.
- Preliminary clinical results from the MGC028 dose-escalation study in late 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MacroGenics (MGNX)?
MacroGenics (MGNX) most recently closed at 4.13 USD, a +1.23% move versus the previous session.
What is the market cap of MacroGenics (MGNX)?
MacroGenics currently has a market capitalization of 257M USD on BioPharmSignal.
What does MacroGenics do?
Antibody Engineering Company MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates. ADC Portfolio MGC026 targets B7-H3 and is in Phase 1 dose expansion, while MGC028 targets ADAM9 and is in Phase 1 dose escalation across advanced solid tumors. Focused R&D...
On which exchange is MGNX stock listed?
MacroGenics (MGNX) is associated with NASDAQ, United States, Biopharma.
What is lorigerlimab?
MGC026 and lorigerlimab clinical data presentations at ESMO 2026.
Which conditions is MacroGenics targeting with lorigerlimab?
MacroGenics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does MacroGenics describe recent progress with lorigerlimab?
MGC026 and lorigerlimab clinical data presentations at ESMO 2026.
What is Antibody?
Antibody Engineering Company MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates.